Clinical Trial Update: Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating vaccine therapy with GM-CSF for low- or intermediate-risk myelodysplastic syndrome. The document provides an update and does n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Leukine (sargramostim)
• Vaccine Therapy (experimental)

Snippet

Sponsor: The Vaccine Company | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: UNKNOWN